Maze Therapeutics Secures Up To $200M Term Loan Facility from Hercules Capital
MAZE has more than doubled off its 52-week low of $6.71.
Summary
Maze Therapeutics has secured a new senior secured term loan facility of up to $200 million from Hercules Capital, with an initial $40 million funded, replacing its previous loan agreement.
Key Events · Financing and Capital Events · MAZE
-
New Loan Facility Secured
Maze Therapeutics entered into a Loan and Security Agreement with Hercules Capital, Inc. for a senior secured term loan facility of up to $200 million.
-
Initial Funding Received
An initial term loan of $40 million was funded on February 4, 2026, providing approximately $38.4 million in net proceeds after fees.
-
Additional Capital Available
Up to an additional $160 million in term loans is available over 60 months, contingent on satisfying certain conditions, financial covenants, and performance milestones.
-
Loan Terms and Security
The facility has a maturity date of February 1, 2031, accrues interest based on the prime rate, and is secured by a first lien on substantially all of the company's assets.
Analysis · MAZE · Life Sciences
Maze Therapeutics has secured a substantial new senior secured term loan facility, providing significant capital to support its operations and development. The initial funding of $40 million, with an additional $160 million available, represents a material liquidity injection for the company. This financing extends the company's financial runway and replaces its previous loan agreement with Banc of California, streamlining its debt structure. The facility is secured by a first lien on substantially all company assets and includes customary covenants and performance milestones for future tranches. Securing this financing while the stock trades near its 52-week high indicates a strong financial position and investor confidence.
At the time of this filing, MAZE was trading at $48.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $6.71 to $48.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.